However, despite these promising results in MS, a major barrier to widespread adoption of NfL assessment in MS research and clinical practice has been the need for CSF sampling, a problem overcome by use fourth-generation immunoassays, which allow evaluation of serum NfL levels [155]. This evidence concerns the gene NEFL and myeloid sarcoma.